An activist shareholder group aptly named Hope for MannKind has gone public with a campaign to reform the marketing strategy for Afrezza, an inhalable form of insulin and the only commercial product of MannKind Corp...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 26 biweekly issues
  • Subscriber-only digital content for prime stories
  • Book of Lists — the most comprehensive business resource in the Valley region
Yours for only $49